论文部分内容阅读
目的 :旨在评价新铂类化合物N 烷基亚胺二乙酸二氨铂 (Ⅱ )配合物 (NMDA)体内抑瘤作用。方法 :采用小鼠移植性腹水瘤和实体瘤模型 ,检测生命延长率或瘤重抑制率。结果显示 ,对小鼠移植性腹水瘤艾氏腹水癌有较高疗效 ,当剂量为 75mg/kg时 ,生命延长率达 112 3% ;当剂量为 50、 75mg/kg时 ,对小鼠移植性实体瘤S180 的瘤重抑制率分别为 30 6 %和 4 3 9% ;对小鼠移植性实体瘤G4 2 2 有轻微的抑制作用 ;对肝癌H2 2 无抑制作用。
PURPOSE: To evaluate the antitumor effect of NMDA, a new platinum-based compound N-alkyliminodiacetic acid (NMDA) in vivo. Methods: Mouse transplanted ascites tumors and solid tumor models were used to detect the prolongation of life or tumor weight inhibition rate. The results showed that mice with transplanted ascites tumors had high efficacy in Ehrlich ascites carcinoma. When the dose was 75 mg/kg, the life prolongation rate was 112 3%; when the dose was 50, 75 mg/kg, the transplantability to mice The tumor weight inhibition rate of solid tumor S180 was 30.6 % and 43.9 % respectively. It had a slight inhibitory effect on transplanted solid tumor G4 2 2 and no inhibitory effect on liver cancer H2 2.